Presentation (CTI)

OBJECTIVES: To describe the economic outcomes resulting from the implementation of a pharmacotherapeutic management program in oncology patients.
METHODS: A cross-sectional descriptive study was conducted in a cohort of patients diagnosed with cancer who were enrolled in a pharmacotherapeutic management program at an outpatient healthcare institution inin 2024. A systematic follow-up of pharmacological therapy was carried out to identify medication errors and both administrative and clinical inefficiencies, which were subsequently addressed to ensure the appropriateness, adherence, safety, and effectiveness of treatment, as well as to promote the rational use of healthcare resources. A univariate analysis was performed using R Core Team software, version 4.2 (2022).
RESULTS: A total of 8,571 patients were evaluated, with a mean age of 59 years (SD: 20), of whom 65.4% were female. A total of 2,559 errors and inefficiencies were identified, occurring most frequently among patients with breast cancer (44.5%), prostate cancer (7.8%), myeloid leukemia (5.7%), central nervous system cancer (5.4%), and multiple myeloma (5.3%). The most common issues included medication authorization errors (29.3%), suspended treatments that remained active (27.8%), and duplicate medical orders (23.7%). The most frequently involved drug classes were antihormonal agents (28.9%), kinase inhibitors (24.6%), antimetabolites (7.1%), antiandrogens (6.8%), and alkylating agents (5.5%). The pharmaceutical interventions implemented resulted in an estimated cost savings of COP 14,833,594,169 (USD 3,475,888).
CONCLUSIONS: The implementation of pharmacotherapeutic management programs for oncology patients contributes not only to improved clinical outcomes but also to significant economic savings, supporting the sustainability of the healthcare system.